Nortey Jeremy, Smith David, Seitzman Gerami D, Gonzales John A
School of Medicine, University of North Carolina, Chapel Hill, NC, United Statesa.
Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, CA, United States.
Front Pharmacol. 2022 Jan 31;12:769909. doi: 10.3389/fphar.2021.769909. eCollection 2021.
Corneal neuropathic pain can be difficult to treat, particularly due to its lack of response to standard dry eye therapies. We describe a variety of topical therapeutic options that are available to treat corneal neuropathic pain with a significant or primary peripheral component. We also describe possible mechanisms of action for such topical therapies. Topical corticosteroids and blood-derived tear preparations can be helpful. Newer therapies, including topical lacosamide and low-dose naltrexone are emerging therapeutic options that may also be considered. Corneal neuropathic pain with a significant peripheral component may be managed with a variety of topical therapeutic options.
角膜神经性疼痛可能难以治疗,尤其是因为它对标准的干眼治疗方法没有反应。我们描述了多种局部治疗选择,可用于治疗具有显著或主要外周成分的角膜神经性疼痛。我们还描述了此类局部治疗的可能作用机制。局部用皮质类固醇和血液来源的泪液制剂可能会有帮助。包括局部用拉科酰胺和低剂量纳曲酮在内的新疗法正在成为可供考虑的新兴治疗选择。具有显著外周成分的角膜神经性疼痛可以通过多种局部治疗选择来处理。